In preclinical models, it has been observed that the overexpression of ABCB1 and ABCG2 in CRC cells, as well as aberrant regulation of WNT/β-catenin and active glycogen synthase kinase 3-beta (GSK3β) signaling, may lead to resistance to gedatolisib [28,74]. The gene discussed is GSK3B; the disease is colorectal carcinoma.